Literature DB >> 25534198

Treatment of pituitary tumours in 2014: Advances in therapy of adenomas secreting GH, ACTH and TSH.

Annamaria Colao1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25534198     DOI： 10.1038/nrendo.2014.227

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

Review 1.  Cushing's syndrome.

Authors:  John Newell-Price; Xavier Bertagna; Ashley B Grossman; Lynnette K Nieman
Journal:  Lancet       Date:  2006-05-13       Impact factor: 79.321

Review 2.  Expert consensus document: A consensus on the medical treatment of acromegaly.

Authors:  Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2014-02-25       Impact factor: 43.330

3.  Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.

Authors:  Shozo Yamada; Noriaki Fukuhara; Kentaro Horiguchi; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Akira Takeshita; Yasuhiro Takeuchi; Junko Ito; Naoko Inoshita
Journal:  J Neurosurg       Date:  2014-09-19       Impact factor: 5.115

4.  2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.

Authors:  P Beck-Peccoz; A Lania; A Beckers; K Chatterjee; J-L Wemeau
Journal:  Eur Thyroid J       Date:  2013-05-07

5.  Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?

Authors:  Federico Gatto; Ludovica F Grasso; Elena Nazzari; Thomas Cuny; Pasquale Anania; Carolina Di Somma; Annamaria Colao; Gianluigi Zona; Georges Weryha; Rosario Pivonello; Diego Ferone
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

6.  A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.

Authors:  Joost van der Hoek; Wouter W de Herder; Richard A Feelders; Aart-Jan van der Lely; Piet Uitterlinden; Viktor Boerlin; Christian Bruns; Kwai W Poon; Ian Lewis; Gisbert Weckbecker; Tillmann Krahnke; Leo J Hofland; Steven W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

7.  Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.

Authors:  Robert R Henry; Theodore P Ciaraldi; Debra Armstrong; Paivi Burke; Monica Ligueros-Saylan; Sunder Mudaliar
Journal:  J Clin Endocrinol Metab       Date:  2013-06-03       Impact factor: 5.958

8.  Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.

Authors:  Rosario Pivonello; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Andrew Trovato; Gareth Hughes; Luiz R Salgado; André Lacroix; Jochen Schopohl; Beverly M K Biller
Journal:  Clin Endocrinol (Oxf)       Date:  2014-03-27       Impact factor: 3.478

9.  High variability in baseline urinary free cortisol values in patients with Cushing's disease.

Authors:  S Petersenn; J Newell-Price; J W Findling; F Gu; M Maldonado; K Sen; L R Salgado; A Colao; B M K Biller
Journal:  Clin Endocrinol (Oxf)       Date:  2013-07-15       Impact factor: 3.478

10.  Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

Authors:  A Colao; M D Bronstein; P Freda; F Gu; C-C Shen; M Gadelha; M Fleseriu; A J van der Lely; A J Farrall; K Hermosillo Reséndiz; M Ruffin; Y Chen; M Sheppard
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958
  10 in total
  1 in total

Review 1.  Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.

Authors:  Annamaria Colao; Filomena de Nigris; Roberta Modica; Claudio Napoli
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-15       Impact factor: 5.555
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.